Table 1 Patient characteristics.
FMD (N = 65) | Regular diet (N = 64) | |
|---|---|---|
Median age (range), Years | 49.0 (31–71) | 51.0 (27–71) |
Median body mass index (range), kg/m2 | 25.7 (19.8–41.2) | 26.0 (19.7–39.0) |
WHO status | ||
Grade 0 | 61 (93.8%) | 60 (93.8%) |
Grade 1 | 3 (4.6%) | 4 (6.3%) |
Unknown | 1 (1.5%) | 0 (0%) |
Menopausal status | ||
Pre/Peri | 27 (41.5%) | 31 (48.4%) |
Post | 38 (58.5%) | 31 (48.4%) |
Unknown | 0 (0%) | 2 (3.1%) |
T-classification | ||
T1 | 5 (7.7%) | 6 (9.4%) |
T2 | 42 (64.6%) | 41 (64.1%) |
T3 | 17 (26.2%) | 15 (23.4%) |
T4 | 1 (1.5%) | 2 (3.1%) |
N-classification | ||
N0 | 29 (44.6%) | 33 (51.6%) |
N1 | 28 (43.1%) | 26 (40.6%) |
N2 | 7 (10.8%) | 4 (6.3%) |
N3 | 1 (1.5%) | 1 (1.6%) |
Stage | ||
I (ineligible) | 0 (0%) | 1 (1.6%) |
II | 51 (78.5%) | 48 (75.0%) |
III | 14 (21.5%) | 15 (23.4%) |
HR status | ||
ER−/PR− | 14 (21.5%) | 7 (10.9%) |
ER-/PR unknown | 0 (0%) | 1 (1.6%) |
ER+/PR− | 9 (13.8%) | 9 (14.1%) |
ER+/PR+ | 42 (64.6%) | 47 (73.4%) |
Chemotherapy regimen | ||
AC-T | 52 (80.0%) | 47 (73.4%) |
FEC-T | 13 (20.0%) | 17 (26.6%) |
Grade (BR) | ||
I | 2 (3.1%) | 2 (3.1%) |
II | 43 (66.2%) | 42 (65.6%) |
III | 20 (30.8%) | 19 (29.7%) |
Unknown | 0 (0%) | 1 (1.6%) |
Tumor type | ||
Ductal | 53 (81.5%) | 49 (76.6%) |
Lobular | 9 (13.8%) | 13 (20.3%) |
Other | 3 (4.6%) | 2 (3.1%) |
